Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium...( Poster to be Presented at the 47t...),Health

Poster to be Presented at the 47th Annual Interscience Conference on

Antimicrobial Agents and Chemotherapy

LOUISVILLE, Colo., Sept. 19 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that in preclinical studies, its antibacterial candidate REP3123 is shown to inhibit growth and prevent spore-forming of the Gram-positive Clostridium difficile (C. difficile) bacterium without inhibiting other key organisms that are essential for normal intestinal functioning. C. difficile-associated disease (CDAD), a major cause of morbidity among the elderly and hospitalized patients, is acquired by ingesting spores present in the environment that then grow and multiply in the gut. In preclinical studies, REP3123 was superior to two agents widely used to treat C. difficile infections, vancomycin and metronidazole, in preventing the organism from forming spores. The study results suggest that REP3123 has the potential to reduce the presence of spores in the intestine, subsequently preventing dissemination into the environment, thereby potentially reducing outbreak and relapse rates.

These results will be presented on Thursday, September 20, 2007 at 10:00 AM in Room E253D by Ian A. Critchley, Ph.D., Executive Director, Microbiology at Replidyne during poster session 229 titled, "New Agents Active Against Clostridium difficile" at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy held at the McCormick Place conference center in Chicago.

REP3123 is a new narrow spectrum antibacterial agent that in vitro prevents the growth of C. difficile by inhibiting an essential enzyme in the bacterial cell called methionyl tRNA synthetase, which blocks the o
'/>"/>